Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) – Stock analysts at Roth Capital issued their FY2029 EPS estimates for shares of Aptevo Therapeutics in a research note issued on Monday, February 17th. Roth Capital analyst J. Aschoff expects that the biotechnology company will earn $2.84 per share for the year. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($14.81) per share.
Separately, StockNews.com assumed coverage on shares of Aptevo Therapeutics in a research report on Monday, December 9th. They set a “sell” rating on the stock.
Aptevo Therapeutics Stock Performance
Aptevo Therapeutics stock opened at $3.45 on Wednesday. Aptevo Therapeutics has a 1 year low of $3.01 and a 1 year high of $399.60. The company’s 50-day moving average is $4.40 and its two-hundred day moving average is $236.14.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Financial Services Stocks Investing
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Stock Dividend Cuts Happen Are You Ready?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
